Acorn Biomedical

Acorn Biomedical was a private, development-stage biopharmaceutical company focused on ophthalmology and drug-delivery technologies. The company was best known for ACN-1052, an adenosine A3 receptor antagonist being developed for glaucoma and ocular hypertension, and for its T-Fusion platform designed to enable oral delivery of recombinant therapeutic proteins using transferrin-based transport. Publicly accessible sources suggest the company operated from Palo Alto, California and was founded in 2008. While some company directories still label it active, multiple industry databases characterize it as effectively inactive or deadpooled, and there is no clear evidence of an advanced clinical pipeline or ongoing commercialization activity.